ERBB3 and neoplasm: In view of the aberrant expression of HER3 and/or activation of HER3 and its ligand, NRG1 is associated with tumor progression and acquired resistance to EGFR and HER2-targeted therapies, and HER3 emerges as an interesting target [126,127].